Literature DB >> 9382757

Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans.

J Mestecky1, S M Michalek, Z Moldoveanu, M W Russell.   

Abstract

Numerous experiments performed in humans and animals have revealed that stimulation of mucosal lymphoid inductive sites such as intestinal Peyer's patches results in parallel immune responses manifested by the appearance of S-IgA antibodies in the external secretions of remote glands. However, recent experiments suggest that inductive sites associated with the upper respiratory tract, rectum, and perhaps genital tract may also function as sources of lymphoid cells that populate, with some selectivity, certain remote mucosal effector sites. Furthermore, antigen-specific IgA antibodies can be induced in certain secretions (e.g., female genital tract) not only by immunization in the vicinity of corresponding mucosal tissues (e.g., vagina and rectum) but also by oral and especially intranasal immunization. The ineffectiveness of simple delivery of soluble antigens to mucosal membranes for immunization has stimulated extensive studies of strategies for effective delivery systems that would (a) increase the antigen absorption, (b) prevent its degradation, and (c) skew the outcome of immunization to a desired goal (protective response to infectious diseases vs. tolerance; B vs. T cell responses; mucosal vs. systemic). The induction of immune responses at a desired mucosal site can be accentuated with the use of a suitable antigen-delivery system including relevant bacterial or viral vectors, edible transgenic plants expressing microbial antigens, incorporation of antigens in biodegradable microspheres or liposomes, and linkage or coadministration of antigens with cholera toxin B subunit. However, only a few antigen-delivery systems extensively used in animal experimentation have been evaluated for their efficacy in humans. The combination of various immunization routes and the use of suitable antigen-delivery systems may accomplish an important task-the induction of mucosal immune responses at a location relevant to the site of entry of a given pathogen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9382757

Source DB:  PubMed          Journal:  Behring Inst Mitt        ISSN: 0301-0457


  13 in total

1.  Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Authors:  Franck Lemiale; Hedi Haddada; Gary J Nabel; Douglas E Brough; C Richter King; Jason G D Gall
Journal:  Vaccine       Date:  2006-11-28       Impact factor: 3.641

2.  A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses.

Authors:  N K Childers; G Tong; S Mitchell; K Kirk; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

3.  Antigen replacement of domains D2 and D3 in flagellin promotes mucosal IgA production and attenuates flagellin-induced inflammatory response after intranasal immunization.

Authors:  Jingyi Yang; Maohua Zhong; Yan Zhang; Ejuan Zhang; Ying Sun; Yuan Cao; Yaoming Li; Dihan Zhou; Benxia He; Yaoqing Chen; Yi Yang; Jie Yu; Huimin Yan
Journal:  Hum Vaccin Immunother       Date:  2013-02-01       Impact factor: 3.452

4.  Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.

Authors:  Bao-Zhong Wang; Harvinder S Gill; Cheng He; Changbo Ou; Li Wang; Ying-Chun Wang; Hao Feng; Han Zhang; Mark R Prausnitz; Richard W Compans
Journal:  J Control Release       Date:  2014-01-11       Impact factor: 9.776

Review 5.  Linking autoantigen properties to mechanisms of immunity.

Authors:  J Daniel Griffin; Jimmy Y Song; Joshua O Sestak; Brandon J DeKosky; Cory J Berkland
Journal:  Adv Drug Deliv Rev       Date:  2020-04-20       Impact factor: 15.470

6.  Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.

Authors:  H Jakobsen; E Saeland; S Gizurarson; D Schulz; I Jónsdóttir
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

7.  Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses.

Authors:  Lbachir BenMohamed; Radhika Krishnan; Catherine Auge; James F Primus; Don J Diamond
Journal:  Immunology       Date:  2002-05       Impact factor: 7.397

8.  A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.

Authors:  S D Klas; C R Petrie; S J Warwood; M S Williams; C L Olds; J P Stenz; A M Cheff; M Hinchcliffe; C Richardson; S Wimer
Journal:  Vaccine       Date:  2008-08-12       Impact factor: 3.641

9.  Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.

Authors:  H Jakobsen; D Schulz; M Pizza; R Rappuoli; I Jónsdóttir
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

10.  Biodegradable nanoparticle-entrapped vaccine induces cross-protective immune response against a virulent heterologous respiratory viral infection in pigs.

Authors:  Varun Dwivedi; Cordelia Manickam; Basavaraj Binjawadagi; Dechamma Joyappa; Gourapura J Renukaradhya
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.